Company Presentation

Immunophotonics Switzerland (IPS Biopharma AG)

Country:Switzerland and USA
Category:Clinical Stage Developemt Company
Speaker:Dr. Theresa Visarius

Company profile

Immunophotonics Switzerland (IPS Biopharma AG) is a privately owned biotech with an innovation to combat solid metastatic cancers. The company is in phase 2a clinical development of its first asset IP-001, designed to induce tumor-specific immune activation. A single intratumoral injection of IP-001 can ignite a systemically active cancer immunotherapy able to target distant untreated metastases. IP-001 also shows notable promise as a vaccine adjuvant in infectious disease.

Further information

Follow us